Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; the references it cites are not checked yet.

Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes

Open access

Abstract

INTRODUCTION: Published evaluations of sensor glucose monitoring use in insulin treated type 2 diabetes are limited. The aim of this study was to assess the impact of flash glucose-sensing technology as a replacement for self-monitoring of blood glucose (SMBG) over a 12-month period in participants with type 2 diabetes who were on intensive insulin therapy. METHODS: An open-label, randomized, controlled study in adults with type 2 diabetes on intensive insulin therapy from 26 European diabetes centers aimed at assessing flash glucose sensing technology was conducted. Participants (N = 224) were randomized (1:2 respectively) to a control group (n = 75) that used SMBG (FreeStyle Lite™) or to an intervention group (n = 149) which used sensor glucose data (FreeStyle Libre™ Flash Glucose Monitoring System) for self-management over 6 months. All intervention group participants who completed the 6-month treatment phase continued into an additional 6-month open-access phase. RESULTS: A total of 139 intervention participants completed the 6-month treatment phase and continued into the open-access phase. At 12 months (end of open-access period), time in hypoglycemia [sensor glucose <3.9 mmol/L (70 mg/dL)] was reduced by 50% compared to baseline [-0.70 ± 1.85/24 h (mean ± standard deviation); p = 0.0002]. Nocturnal hypoglycemia [2300 to 0600 hours, <3.9 mmol/L (70 mg/dL)] was reduced by 52%; p = 0.0002. There was no change in time in range [sensor glucose 3.9-10.0 mmol/L (70-180 mg/dL)]. SMBG testing fell from a mean of 3.9 (median 3.9) times/day at baseline to 0.2 (0.0), with an average frequency of sensor scanning of 7.1 (5.7) times/day at 12 months, and mean sensor utilization was 83.6 ± 13.8% (median 88.3%) during the open-access phase. During this 6-month extension period no device-related serious adverse events were reported. Nine participants reported 16 instances of device-related adverse events (e.g. infection, allergy) and 28 participants (20.1%) experienced 134 occurrences of anticipated skin symptoms/sensor-insertion events expected with device use (e.g. erythema, itching and rash). CONCLUSION: The use of flash glucose-sensing technology for glycemic management in individuals with type 2 diabetes treated by intensive insulin therapy over 12 months was associated with a sustained reduction in hypoglycemia and safely and effectively replaced SMBG. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT02082184.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s13300-017-0255-6

Cites

Statistics

Figures

Fig. 1 Trial profile. ITT Intention to treat
Fig. 1 Trial profile. ITT Intention to treatCC BY-NC · PubMed Central
Fig. 2 Difference from baseline for time in range and hypoglycemia measures at 12 months. Rescaled confidence intervals are confidence intervals for the difference from baseline expressed as a percentage of the baseline mean
Fig. 2 Difference from baseline for time in range and hypoglycemia measures at 12 months. Rescaled confidence intervals are confidence intervals for the difference from baseline expressed as a percentage of the baseline meanCC BY-NC · PubMed Central
Fig. 3 Summaries of all glycemic measures during the day (0600–2300) (a) and during the night (2300–0600) (b). Difference from baseline for glycemic measures at 12 months post-baseline. Rescaled confidence intervals are confidence intervals for the difference from baseline expressed as a percentage of the baseline mean
Fig. 3 Summaries of all glycemic measures during the day (0600–2300) (a) and during the night (2300–0600) (b). Difference from baseline for glycemic measures at 12 months post-baseline. Rescaled confidence intervals are confidence intervals for the difference from baseline expressed as a percentage of the baseline meanCC BY-NC · PubMed Central
Fig. 4 Blood glucose monitoring tests and sensor scans frequency per day by study period. BGM Blood glucose monitoring
Fig. 4 Blood glucose monitoring tests and sensor scans frequency per day by study period. BGM Blood glucose monitoringCC BY-NC · PubMed Central
Fig. 5 Summaries of glycemic measures for participants aged <65 years (a) and aged ≥65 years (b). Difference from baseline for glycemic measures at 12 months. Rescaled confidence intervals are confidence intervals for the difference from baseline expressed as a percentage of the baseline mean
Fig. 5 Summaries of glycemic measures for participants aged <65 years (a) and aged ≥65 years (b). Difference from baseline for glycemic measures at 12 months. Rescaled confidence intervals are confidence intervals for the difference from baseline expressed as a percentage of the baseline meanCC BY-NC · PubMed Central
Fig. 6 Significantly reduced time in hypoglycemia is observed as soon as sensor glucose results can be utilized by the participants at the end of the baseline phase and is sustained for 12 months
Fig. 6 Significantly reduced time in hypoglycemia is observed as soon as sensor glucose results can be utilized by the participants at the end of the baseline phase and is sustained for 12 monthsCC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 22 · Cited by 188

Metadata

Authors
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G.
Affiliations
  • German Diabetes Center Mergentheim (DE)
  • Centre Hospitalier Universitaire de Toulouse (FR)
  • University of Leeds (GB)
  • Université Paris Diderot (FR)
  • Ipswich Hospital (GB)
Corresponding author
Haak, Thomas
Venue
Diabetes Therapy
Published
2017-04-11
Volume
8
Issue
3
Pages
573-586
ISSN
  • 1869-6953 (ISSN-L)
  • 1869-6961
OpenAlex
W2606131208
Cited by
188
References
22
Citations by year
2026: 7 · 2025: 7 · 2024: 26 · 2023: 18 · 2022: 35 · 2021: 32 · 2020: 21 · 2019: 19 · 2018: 18 · 2017: 5
FWCI
13.63
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc
  • creativecommons.org/licenses/by/4.0 (tdm)
Locations
  • Diabetes Therapy (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
Funders
Abbott Diabetes Care
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
flash glucose monitoring, continuous glucose monitoring, type 2 diabetes, intensive insulin therapy, self-monitoring of blood glucose, hypoglycemia, nocturnal hypoglycemia, time in range, device-related adverse events, diabetes self-management, FreeStyle Libre

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. https://app.cochat.ai/papers/10.1007/s13300-017-0255-6
The paper
Haak, T., Hanaire, H., Ajjan, R., Hermanns, N., Riveline, J.-P., & Rayman, G. (2017). Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. Diabetes Therapy. https://doi.org/10.1007/s13300-017-0255-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.